Patents by Inventor Rongtuan Lin

Rongtuan Lin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 5'-TRIPHOSPHATE OLIGORIBONUCLEOTIDES
    Publication number: 20140287023
    Abstract: 5?-triposphate oligoribonucleotides, pharmaceutical compositions comprising said 5?-triposphate oligoribonucleotides, and methods of using said 5?-triposphate oligoribonucleotides to treat viral infections are disclosed.
    Type: Application
    Filed: February 11, 2014
    Publication date: September 25, 2014
    Inventors: John Hiscott, Rongtuan Lin, Meztli Arguello
  • Hybrid-ionone and curcumin molecules as anticancer agents
    Patent number: 8470889
    Abstract: The present invention relates to the synthesis of a series of ionone and curcumin derivatives as multi-targeting agents effective against both hormone-sensitive and hormone-independent cancers. In particular, the present invention is directed to a distinct class of bifunctional antiandrogens, which inhibit both AR and IKBkinases (IKK). A series of ionone-based chalcones were synthesized and their in vitro cytotoxicity against prostate cancer cell lines were demonstrated. A series of derivatives formed by reacting ionone-based chalcones and hydrazines demonstrate substantial antiproliferative activities in prostate cancer, breast cancer and lung cancer cell lines.
    Type: Grant
    Filed: November 25, 2009
    Date of Patent: June 25, 2013
    Assignee: TRT Pharma Inc.
    Inventors: Jian Hui Wu, Gérald Batist, Jinming Zhou, Guoyan Geng, Rongtuan Lin, Yi Li
  • HYBRID-IONONE AND CURCUMIN MOLECULES AS ANTICANCER AGENTS
    Publication number: 20110230488
    Abstract: The present invention relates to the synthesis of a series of ionone and curcumin derivatives as multi-targeting agents effective against both hormone-sensitive and hormone-independent cancers. In particular, the present invention is directed to a distinct class of bifunctional antiandrogens, which inhibit both AR and IKBkinases (IKK). A series of ionone-based chalcones were synthesised and their in vitro cytotoxicity against prostate cancer cell lines were demonstrated. A series of derivatives formed by reacting ionone-based chalcones and hydrazines demonstrate substantial antiproliferative activities in prostate cancer, breast cancer and lung cancer cell lines.
    Type: Application
    Filed: November 25, 2009
    Publication date: September 22, 2011
    Applicant: TRT PHARMA INC.
    Inventors: Jian Hui Wu, Gerald Batist, Jinming Zhou, Guoyan Geng, Rongtuan Lin